OncoMed's Cancer Stem Cell Therapies Could Provide Outsized Gains For Investors
BPD Research • 17 Comments
BPD Research • 17 Comments
Thu, May 5, 4:47 PM
Wed, May 4, 5:35 PM
- ABCO, ABTL, ACAD, ACET, AHS, AHT, AIRM, AL, ALEX, AMBR, AMH, ANET, APLE, ASYS, ATHX, ATVI, ATW, BBG, BCEI, BIO, BIOS, BLDR, BOJA, CAA, CARA, CERN, CINR, CLNE, CLVS, CMLS, CPA, CTRL, CYBR, CZR, DATA, DCT, DEPO, DIOD, DK, DKL, DV, DWA, EBS, ECOM, ED, EFC, EGAN, EGL, EGN, EGY, ELON, ENDP, ENV, EOG, ERII, ESL, EVC, EVDY, EVHC, FCE.A, FEYE, FISV, FLR, FPRX, FTD, GBDC, GEOS, GERN, GPRO, GSAT, GST, GUID, GXP, HLF, HTGC, ICPT, IMMR, IMPV, INAP, JCOM, LADR, LOCO, MAIN, MCHX, MDR, MDRX, MDVN, MELI, MHK, MITT, MNTX, MRIN, MSI, MTD, MTZ, NBIX, NGVC, NSTG, NWSA, OLED, OMED, OUT, OVAS, PACD, PCTY, PEGA, PETX, PKI, PMT, POST, PRSS, PTCT, PTLA, QLGC, RPTP, RRMS, RWT, SAAS, SEM, SEMG, SNCR, SPPI, SPWR, SPXC, SQ, SSNC, SWIR, TCRD, TEAM, TRMR, TRUE, TRQ, TRUP, TSRO, TWOU, UBNT, UEPS, UNXL, WAGE, WAIR, WEB, WIFI, WING, XNPT, Y, YELP
Thu, Mar. 10, 4:08 PM
Wed, Mar. 9, 5:35 PM
Nov. 5, 2015, 7:08 AM
- OncoMed (NASDAQ:OMED): Q3 EPS of -$0.81 misses by $0.04.
- Revenue of $4.69M (-75.3% Y/Y) misses by $1.15M.
Nov. 4, 2015, 5:30 PM
- AAWW, ACIW, ACRE, ACTA, AES, AGIO, AGU, AINV, ALSK, AMCX, AMED, AMRC, ANSS, APA, ATHM, AZN, BBEP, BCE, BCRX, BDBD, BEE, BR, CCC, CCOI, CECE, CELG, CLDT, CNK, CNP, CNQ, CNSL, CONE, COTY, CROX, CSTM, CWEI, DNR, DUK, EGL, ENB, ENDP, ENOC, ESI, FUN, GEO, GLOG, GLP, GOGO, HFC, HGG, HII, HRC, INSY, IRC, IT, ITC, ITG, KATE, KOP, LAMR, LBY, LINE, LPI, LXP, MEG, MGA, MITL, MPEL, MPW, MSG, MSO, MVIS, MZOR, NDLS, NGS, NHI, NILE, NRP, OGE, OMED, PBH, PDCE, PRFT, PRIM, PWE, PWR, RDUS, RGEN, RGLD, RICE, RL, RLGY, RRD, RVLT, RWLK, SCOR, SEAS, SFM, SFY, SJI, SNSS, SPAR, SRC, SRPT, SSTK, STN, STWD, SYMC, TAP, TDC, TE, THS, TIME, TK, TLP, TNK, TRXC, TU, USAC, VC, VER, VIVO, WAC, WIN, WPP, ZEUS
Aug. 10, 2015, 4:35 PM
- OncoMed (NASDAQ:OMED): Q2 EPS of -$0.72 misses by $0.23.
- Revenue of $4.7M (-21.9% Y/Y) misses by $8M.
Aug. 9, 2015, 5:35 PM| Aug. 9, 2015, 5:35 PM | 13 Comments
May 7, 2015, 4:18 PM
- OncoMed (NASDAQ:OMED): Q1 EPS of -$0.49 misses by $0.14.
- Revenue of $9.69M (+61.0% Y/Y) misses by $5.66M.
Mar. 12, 2015, 4:11 PM
- OncoMed (NASDAQ:OMED): Q4 EPS of -$0.50 misses by $0.23.
- Revenue of $8.51M (-55.2% Y/Y) misses by $9.73M.
Mar. 11, 2015, 5:35 PM
Nov. 4, 2014, 5:36 PM
- OncoMed (NASDAQ:OMED): Q3 EPS of -$0.18 beats by $0.12.
- Revenue of $19M (+47.3% Y/Y) beats by $4.25M.
Aug. 7, 2014, 9:06 AM
- OncoMed Pharmaceuticals (NASDAQ:OMED): Q2 EPS of -$0.53 may not be comparable to consensus of -$0.03.
- Revenue of $6M (+104.8% Y/Y) misses by $15.28M.
May 8, 2014, 9:35 AM
- OncoMed (OMED): Q1 EPS of -$0.47 misses by $0.34.
- Revenue of $6.01M (+2.93M% Y/Y) misses by $10.57M.
Mar. 18, 2014, 8:35 AM
- OncoMed Pharmaceuticals (OMED): Q4 EPS of -$0.15.
- Revenue of $19M misses by $1.97M.
OncoMed Pharmaceuticals, Inc. is a clinical development-stage biotechnology company that discovers and develops first-in-class protein therapeutics targeting cancer stem cells. The company has established a library of antibodies to cancer stem cell proteins for the treatment of solid tumors such... More
Country: United States
Other News & PR